Yanina Jansen - Concepedia

Author

Yanina Jansen

Also Known As

Y. Jansen, Y.J.L. Jansen, Yanina J. Jansen, Yanina J. L. Jansen, Yanina J.L. Jansen, Yanina Jansen, Yanina Jeanne Leona Jansen

Publications

1.5K

Citations

H-Index

Concepts

All Affiliations

Universitair Ziekenhuis Brussel Vrije Universiteit Brussel Erasmus Hospital Université Libre de Bruxelles Ghent University Hospital

About

Yanina Jansen is an author at Universitair Ziekenhuis Brussel specializing in medicine, pathology, and dermatology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	7	7	354
2	Immunology	4	4	143
3	Health Sciences	1	1	13
4	Cell Biology	1	1	19
5	Diagnostic Sciences	1	1	13

Yanina Jansen

Publications

1.3K

Citations

H-Index

Page 1

	Year	Citations
Incidence of Thyroid-Related Adverse Events in Melanoma Patients Treated With Pembrolizumab Jeroen de Filette, Yanina Jansen, Max Schreuer, The Journal of Clinical Endocrinology & Metabolism	2016	242
Discontinuation of anti-PD-1 antibody therapy in the absence of disease progression or treatment limiting toxicity: clinical outcomes in advanced melanoma Yanina Jansen, Elisa A. Rozeman, Robert M. Mason, Annals of Oncology	2019	222
Combination of dabrafenib plus trametinib for BRAF and MEK inhibitor pretreated patients with advanced BRAFV600-mutant melanoma: an open-label, single arm, dual-centre, phase 2 clinical trial Max Schreuer, Yanina Jansen, Simon Planken, The Lancet Oncology Single ArmAdvanced Brafv600-mutant MelanomaMedicineMelanomaPathology	2017	179
Quantitative assessment of BRAF V600 mutant circulating cell-free tumor DNA as a tool for therapeutic monitoring in metastatic melanoma patients treated with BRAF/MEK inhibitors Max Schreuer, Geert Meersseman, Sari Van Den Herrewegen, Journal of Translational Medicine	2016	136
Undetectable circulating tumor DNA (ctDNA) levels correlate with favorable outcome in metastatic melanoma patients treated with anti-PD1 therapy Teofila Seremet, Yanina Jansen, Simon Planken, Journal of Translational Medicine	2019	116
A randomized controlled phase II clinical trial on mRNA electroporated autologous monocyte-derived dendritic cells (TriMixDC-MEL) as adjuvant treatment for stage III/IV melanoma patients who are disease-free following the resection of macrometastases Yanina Jansen, Vibeke Krüse, Jurgen Corthals, Cancer Immunology Immunotherapy MelanomaImmunologyTherapeutic VaccineAdjuvant TreatmentAutoimmunity	2020	70
Granulomatous nephritis and dermatitis in a patient with BRAF V600E mutant metastatic melanoma treated with dabrafenib and trametinib Yanina Jansen, Peter Janssens, Anne Hoorens, Melanoma Research Renal PathologyImmunologyPathologyDermatologyImmunotherapy	2015	43
A Comprehensive Analysis of Baseline Clinical Characteristics and Biomarkers Associated with Outcome in Advanced Melanoma Patients Treated with Pembrolizumab Gil Awada, Yanina Jansen, Julia Katharina Schwarze, Cancers	2021	35
Phase I clinical trial of decitabine (5-aza-2'-deoxycytidine) administered by hepatic arterial infusion in patients with unresectable liver-predominant metastases Yanina Jansen, Gontran Verset, Kelly Schats, ESMO Open	2019	34
Molecular and epigenetic features of melanomas and tumor immune microenvironment linked to durable remission to ipilimumab-based immunotherapy in metastatic patients Teofila Seremet, Alexander Koch, Yanina Jansen, Journal of Translational Medicine	2016	33

Page 1